It's the first substitution therapy approved in Europe to target the underlying cause of PKU by helping the body to break down Phe.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.